On Thursday shares of Mondelez International, Inc. (NASDAQ:MDLZ) closed at $34.66. Company’s sales growth for last 5 years was -2.40% and EPS growth for next 5 years is recorded as 8.80%. Mondelez International Inc. (NASDAQ:MDLZ) is expanding a presence in soccer initiated last year with a two-year deal to become the Official Snacks of Major League Soccer (MLS). The deal stakes a larger position for the CPG giant, which last year became the Official Snacks of U.S. Soccer.
Synthetic Biologics Inc. (NYSEMKT:SYN) in last trading activity increased 6.30% to close at $2.53. Company weekly performance is -15.67% while its quarterly performance stands at 68.67%. Synthetic Biologics Inc. (NYSEMKT:SYN) is -30.49% away from its 52 week high. Synthetic Biologics, Inc. (NYSEMKT:SYN) announced positive pharmacokinetics (PK) results from both the Phase 1a and 1b studies of SYN-004, which is being developed to protect the microbiome and prevent Clostridium difficile (C. difficile) infection.
On Thursday shares of Goldcorp Inc. (NYSE:GG) closed at $18.61. Company’s sales growth for last 5 years was 4.80% and EPS growth for next 5 years is recorded as 11.10%. Zacks reaffirmed their neutral rating on shares of Goldcorp (NYSE:GG) in a research note issued to investors on Thursday. The firm currently has a $20.00 price target on the stock.
Eli Lilly and Company (NYSE:LLY) in last trading activity advanced 0.92% to close at $74.22. Company weekly performance is 6.70% while its quarterly performance stands at 7.92%. Eli Lilly and Company (NYSE:LLY) is -0.46% away from its 52 week high. Eli Lilly and Company (NYSE: LLY) and Hanmi Pharmaceutical Co., Ltd. (Hanmi) announced they have entered into an exclusive license and collaboration agreement for the development and commercialization of Hanmi’s oral Bruton’s tyrosine kinase (BTK) inhibitor, HM71224, for the treatment of autoimmune and other diseases. – See more at: http://www.pharmacytimes.com/market-news/Lilly-and-Hanmi-Announce-an-Exclusive-License-and-Collaboration-Agreement-for-the-Development-and-Commercialization-of-an-Immunological-Therapy#sthash.3Yczp4jh.dpuf
On last trading day Kayne Anderson Energy Development Company (NYSE:KED) decreased -3.04% to close at $27.44. Its volatility for the week is 3.86% while volatility for the month is 2.69%. KED’s sales growth for past 5 years was 2.50% and its EPS growth for past 5 years was 23.70%. Kayne Anderson Energy Development Company (NYSE:KED) monthly performance is -19.51%. Kayne Anderson Energy Development Company (NYSE:KED) announced that it reached a conditional agreement with an institutional investor relating to a private placement of $25 million of Mandatory Redeemable Preferred Shares (the “MRP Shares”). The MRP Shares will mature five years from issuance and pay quarterly cash dividends at a rate of 3.37% per annum.